Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib and endocrine therapy in HR+/HER2- HER2-enriched breast cancer
NCT04460430Phase 2Terminated
- Sponsor
- SOLTI
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Countries
- 2
01
Overview
A Phase 2 trial of neratinib in breast cancer, sponsored by SOLTI. Started Jul 2020; status: terminated.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04460430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460430.